Tolvaptan
- PDF / 169,381 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 58 Downloads / 145 Views
1
Tolvaptan Hypernatraemia: case report A 79-year-old woman developed hypernatraemia during treatment with tolvaptan for elephantiasis nostras verrucosa (ENV). The woman was repeatedly hospitalised due to cellulitis owing to obesity and lymphoedema despite compression bandages and furosemide being used to treat the oedema in her lower limbs. Her features were consistent with a diagnosis of ENV. After the treatment of her cellulitis, the leg oedema remained. Therefore, tolvaptan 7.5mg [route and frequency not stated] therapy was commenced. However, she could not tolerate tolvaptan due to hypernatraemia [duration of treatment to reaction onset not stated]. The dose of tolvaptan was then reduced to 3.75mg. One year after the start of tolvaptan therapy, the woman’s body weight decreased, and the ENV improved without any side effects. Author comment: "Tolvaptan (7.5 mg) therapy was initiated. However, our patient could not tolerate this treatment because of hypernatremia". Eda Y, et al. Tolvaptan for the treatment of elephantiasis Nostras verrucosa. Internal Medicine 58: 3347-3348, No. 22, Jan 2019. Available from: URL: http:// 803440951 doi.org/10.2169/internalmedicine.2815-19 - Japan
0114-9954/19/1784-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Dec 2019 No. 1784
Data Loading...
